Omnicell, Inc. · NASDAQ:OMCL
Omnicell — Q3 2023 Earnings Presentation
27 slides from Omnicell's earnings presentation, Nov 2, 2023
Slide 1: Omnicell Investor Relations
ro) Omnicell Investor Relations November 2, 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements’ within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2023 guidance, strategic and growth opportunities, other expectations and other non-historical informa
Slide 3: Our Mission
Our Mission Be the clinician’s most trusted partner for medication management. We are dedicated to continuously deliver innovative technology that helps our customers improve patient care, for everyone. Our Vision Deliver the most compelling automation and services that accelerate pharmacy perfectio
Slide 4: Our Strategy
Our Strategy Fundamentally transform the pharmacy care delivery model by delivering a set of services that touch the entire continuum of care, built on a single cloud platform. Point Central of Care Pharmacy INPATIENT Specialty Retail Pharmacy “a OUTPATIENT Home
Slide 5: Omnicell: Compelling Growth Opportunities
Omnicell: Compelling Growth Opportunities Category creator Leading strategic partner to Resilient, long-term revenue Demonstrated track record of transforming the pharmacy health systems in large and growth accelerated by strong growth built on a platform of care delivery model growing market segmen
Slide 6: The Autonomous Pharmacy Framework — an Industry Vision
The Autonomous Pharmacy Framework — an Industry Vision Non-Au! Pharm: Level 2 cg00g sogeg © 2023 Omnicell, Inc. 6
Slide 7: Our Comprehensive Solutions Fundamentally Deliver Better Healthcare
Our Comprehensive Solutions Fundamentally Deliver Better Healthcare Value Central Pharmacy ia a Inventory Dispensing Service ee = Optimization Service IV Compounding Specialty Service ee 1%, Pharmacy Services Point of (o) Omnicell EnlivenHealth Care Connected Intelligent Infrastructure Inpatient Out
Slide 8: Leader in Large and Growing Segments
Leader in Large and Growing Segments Omnicell is growing its leadership position across a potential $90 Billiont TAM Estimated TAM Opportunity! $22 Billion Retail $90 Billlon+ TOTAL TAM $19 Billion Point of Care $19 Billion Specialty Pharmacy Services $32 Billion Central Pharmacy
Slide 9: Deep Customer Relationships & Robust Backlog
3 Deep Customer + Strong position within the top 300 U.S. health systems Relationships & + Robust backlog of $1215 Billion as of 12/31/2022 Robust Backlog Customers increasingly turning to Omnicell for our platform-based approach to medication management Multiple Growth + Expansion opportunities wit
Slide 10: Advanced Services: Accelerating Recurring Revenue Growth
3) Advanced Services Accelerating Recurring Revenue Growth Advanced Services (% of Total Revenue) Targeting 18% of total revenue for 2023 18% 14% 10% i 2020 2021 2022 2023E les Central Pharmacy Dispensing Service (service portion), IV Compounding Service (service portion), EnlivenHealth solutions, S
Slide 11: Advanced Services Business Model — Customer Example
Advanced Services Business Model — Customer Example Tech-Enabled Services Model (IVCS and CPDS) YEAR1 YEAR 2 YEAR 3 YEAR 4-7 Product Revenue End of year7 Cash Cash Cash Cash TT Recurring Received Received Received Received Net sales type lease Advanced Services Hn balance: $0 Revenue Recurring Recur
Slide 12: Strong Balance Sheet
©) Strong Balance Sheet $2,222M Free cash flow projected ; $1,187M to grow slower than $1,016M EBITDA as Omnicell reinvests in the $447M eau ransformation transfo els ike) $32M Advanced Services Cash and Cash Equivalents Total Assets Total Equity 1.9x Liquidity and capital structure support growth s
Slide 13: Backlog ($Million)
Backlog! ($Million) By type: As of December 31, 2022 As of December 31, 2021 Product Backlog $797 $977 Advanced Services Backlog? $418 $277 Total Backlog $1,215 $1,254 Short-Term Product Backlog $503 $745 Long-Term Product Backlog $294 $232 Short-Term Advanced Services Backlog* $49 $37 Long-Term Adv
Slide 14: Total Year Revenue Composition
Total Year Revenue Composition
Slide 15: Financial Snapshot
Financial Snapshot Q3-2023 YoY Change % Total Revenues $299 Million -14% Non-GAAP Gross Margin % 45.7% -180bps Non-GAAP Operating Expenses $109 Million ~6% Non-GAAP EBITDA $41 Million -33% Non-GAAP Diluted Earnings Per Share $0.62 -38% See Appendix for a reconciliation of Q3-2023 Non-GAAP Gross Marg
Slide 16: Updated 2023 Guidance
Updated 2023 Guidance djusted to include the anticipated ¢ and expected impact of currer Nac onomic headv S 04-2023 i > Leadership position in th ee ~ transformation of healthcar $90 Billion+ TAV2 Bookings! Not guided $850 Million -$950 Million Emerging and scaling of Advanced Total Revenues $247-$2
Slide 17: A Better Way: Our Environment, Social, Governance, and Innovation Strategy
A Better Way: Our Environment, Social, Governance, and Innovation Strategy vw) Environment Innovating for Energy Efficiency Actively contribute to realize 1.5° Celsius future by 2030 Innovation Accelerating for Perfection Design and deliver our products to minimize our environmental footprint while
Slide 18: A Better Way: Our Approach to ESG
A Better Way: Our Approach to ESG Our Approach @ Omnicell uses a risk-based approach designed to strategically align our ESG goals and targets to address the risks we believe are most material to our organization Our Better Way @ In 2021, Omnicell identified 11 material topic areas that our internal
Slide 19: MSCI ESG Research Notice
• • • • • • • • • • • • • THE USE BY OMNICELL, INC. OF ANY MSCI ESG RESEARCH LLC OR ITS AFFILIATES (“MSCI”) DATA, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT, RECOMMENDATION, OR PROMOTION OF OMNICELL, INC. BY MSCI. MSCI SER
Slide 20: We Expect that Omnicell is Positioned to Win
We Expect that Omnicell is Positioned to Win Based on Our Belief that: Y Omnnicell has the right solutions and the right business model to solve the medication management problem that the healthcare system is facing Y Omnicell is positioned as the leading strategic partner to health systems in large
Slide 21: Appendix
Appendix
Slide 22: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended September 30, 2023 2022 Reconciliation of GAAP revenues to non-GAAP revenues: GAAP revenues $ 298,663 $ 348,059 Acquisition accounting impact related to deferred reven
Slide 23: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended September 30, 2023 2022 Reconciliation of GAAP income from operations to non-GAAP income from operations: GAAP income from operations $ 3,712 $ 18,465 GAAP operating i
Slide 24: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended September 30, 2023 2022 Reconciliation of GAAP net income per share - diluted to non-GAAP net income per share - diluted: Shares - diluted GAAP 45,595 45,819 Shares -
Slide 25: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended Three Months Ended Three Months Ended Three Months Ended Year Ended September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 December 31, 2017 Reconciliation
Slide 26: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Quarter Ended Quarter Ended September 30, 2023 September 30, 2023 Convertible senior notes, net $ 568,887 Revolver availability $ 500,000 Cash and cash equivalents (446,840) Cash and cas
Slide 27: Omnicell